Cancer Scienceへの掲載実績
- 14. Ohishi T, Suzuki H, Kaneko MK, Tanaka T, Harakawa A, Yoshida J, Tatsuda D, Kato Y, Kawada M.
Development and Evaluation of Eb4Mab-7-mG2a: A Dual-Action Anti-EphB4 Monoclonal Antibody for Targeted Breast Cancer Therapy
Cancer Sci, https://doi.org/10.1111/cas.70198, 2025 (PDF; preprint)
- 13. Tanaka T, Suzuki H, Ohishi T, Kawada M, Kaneko MK, Kato Y.
Antitumor activities by a humanized cancer-specific anti-podoplanin monoclonal antibody humPMab-117 against human tumors
Cancer Sci,116(8), 2232-2242, https://doi.org/10.1111/cas.70103, 2025 (PDF; preprint)
- 12. Yoneda H, Mitsuhashi A, Yoshida A, Ogino H, Itakura S, Nguyen NT, Nokihara H, Sato S, Shinohara T, Hanibuchi M, Abe S, Kaneko MK, Kato Y, Nishioka Y.
Anti-podoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells
Cancer Sci.,115(2), https://doi.org/10.1111/cas.16046, 2024 (PDF)
- 11. Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y.
Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H2Mab-77-mG2a-f
Cancer Sci., 115(1), 298-309, https://doi.org/10.1111/cas.16008, 2024 (PDF; preprint)
- 10. Goto N, Suzuki H, Zheng L, Okano Y, Okita Y, Watanabe Y, Kato Y, Kato M.
Promotion of squamous cell carcinoma tumorigenesis by oncogene-mediated THG-1/TSC22D4 phosphorylation.
Cancer Sci., 114(10), 3972-3983, http://doi.org/10.1111/cas.15934, 2023 (PDF)
- 9. Fujii K, Morita S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, Yamaguchi K, Abe J, Yamazaki T, Imai T, Sugamura K, Yasuda J, Satoh K, Sato I, Saito-Koyama R, Fujishima F, Sasano H, Kato Y, Matsuura K, Asada Y, Tamai K.
Establishment of a monoclonal antibody against glycosylated CD271 specific for cancer cells in immunohistochemistry
Cancer Sci., 113(8),2878-2887, doi: 10.1111/cas.15340., 2022 (PDF)
- 8. Sakamoto S, Inoue H, Kaneko MK, Ogasawara S, Kajikawa M, Urano S, Ohba SI, Kato Y, Kawada M.
Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy
Cancer Sci., 110(11):3595-3602, https://doi.org/10.1111/cas.14196, 2019, (PDF)
- 7. Sudo H, Tsuji AB, Sugyo A, Saga T, Kaneko MK, Kato Y, Higashi T.
Therapeutic efficacy evaluation of radioimmunotherapy with 90Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma
Cancer Sci., 110(5):1653-1664, https://doi.org/10.1111/cas.13979, 2019 (pdf)
- 6. Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Okada N, Miyamoto R, Sato C, Tobiume M, Otsuka K, Tsuchiya K, Kawazoe K, Ogasawara S, Kato Y, and Nishioka Y.
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in orthotopic xenograft model
Cancer Sci.,107, 1198–1205, 2016(pdf)
- 5. Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.*
(*corresponding author)
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
Cancer Sci.,105(6),744-8,2014 (pdf)
- 4. Moriya K, Kaneko MK, Liu X, Hosaka M, Fujishima F, Watanabe M, Ogasawara S, Sakuma J, Sasahara Y, Kure S, Kato Y*
(*corresponding author)
IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome.
Cancer Sci., 105(3),359-362,2014 (pdf)
- 3. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y*.
(*corresponding author)
Chimeric anti-podoplanin antibody suppresses tumor metastasis via neutralization and antibody-dependent cellular cytotoxicity
Cancer Sci., 103 (11), 1913?1919, 2012 (pdf)
- 2. Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayash T.
Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas with integrated genomic and epigenetic profiles
Cancer Sci.,103(10):1871-9., 2012 (pdf)
- 1. Kato Y*, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y and Narimatsu H.(*corresponding author)
Molecular analysis of pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Cancer Sci, 99(1), 54-61,2008 (pdf)
-
～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～
<日本癌学会内規2017年6月改訂より>
2. (2）評議員の再任資格
以下の要件のいずれかを満たしている評議員は、所定の手続きを経て評議員に再任される。
①原則として、過去3年間に日本癌学会機関誌Cancer Scienceへの論文掲載実績が1報以上ある、
あるいは過去6年間に総説掲載の実績が1報以上、
または、過去6年間に原著論文2報以上の掲載実績を有する。
②通算でCancer Science（JJCRやGANNも含む）への掲載論文総数が10報以上ある。
③過去3年間にCancer Scienceに採択されなかった論文がCancer Medicineに掲載された場合
（Cancer ScienceのEditorからCancer Medicineに投稿することを推奨された論文に限る）も、
Cancer Science１報に準ずるものと考え、その他の日本癌学会の活動への貢献とあわせて
総合的に再任を評価する。
～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～～
業績
